Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.87%
#3 Fabric Protocol Fabric Protocol +18.73%
#4 Cysic Cysic +17.50%
#5 Bedrock Bedrock +10.70%
#6 Cap Cap +8.99%
#7 stake.link stake.link +6.45%
#8 Pons Pons +5.85%
#9 Enso Enso +5.58%
#10 Perle Perle +5.03%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Rang in Aktien #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Aktienkurs
$0.1
Zuletzt synchronisiert: 2024-06-18
Marktkapitalisierung
$1.31M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Pascal Biosciences Inc. (PSCBF)

Kategorie

Healthcare
Operative Marge für Pascal Biosciences Inc. (PSCBF)
Operative Marge zum August 2026 TTM: -133.68%
Laut den neuesten Finanzberichten und dem Aktienkurs von Pascal Biosciences Inc. beträgt die aktuelle operative Marge (TTM) -133.68%. Am Ende des Jahres 2022 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Pascal Biosciences Inc. von 2019 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -133.68% 0.00%
2023 -133.68% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -100.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -100.23%
BE
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.